ADMA Biologics Inc (NASDAQ:ADMA) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.19 per share.
Looking ahead, the full year loss are expected at $ 0.87 per share on the revenues of $ 39.75 million.
Previous Quarter Performance
ADMA Biologics Inc announced loss for the second quarter of $ 0.23 per share, from the revenue of $ 7.79 million. The consensus estimates are loss of $ 0.16 per share from $ 10.57 million in revenue. The bottom line results missed street analysts by $ 0.07 or 43.75 percent, at the same time, top line results fell short of analysts by $ 2.78 million or 26.3 percent.
Stock Performance
Shares of ADMA Biologics Inc traded up $ 0.06 or 2.88 percent on Wednesday, reaching $ 2.14 with volume of 1.70 million shares. ADMA Biologics Inc has traded high as $ 2.22 and has cracked $ 2.09 on the downward trend
The closing price of $ 2.14, representing a 43.45 % increase from the 52 week low of $ 1.45 and a 60.23 % decrease over the 52 week high of $ 5.23.
The company has a market capital of $ 184.79 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 1st October 2020, maintained by Raymond James at Outperform rating, with $ 7.00 target price.
Conference Call
ADMA Biologics Inc will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.admabiologics.com
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency.
